Leave Message

Enroserene · Enrofloxacin Tablets

A fluoroquinolone antimicrobial drug indicated for the treatment of bacterial and mycoplasmal infections in animals.

Available As      Chewable Flavored Tablet

Specification    5mg/tablet * 30 tablets/box; 25mg/tablet * 30 tablets/box

Product Advantage:
1) Ultrafine crushing technology for enhanced absorption efficiency​​
Enroserene employs ultrafine crushing technology to process raw pharmaceutical materials into superfine powder with a particle size of 1μm—significantly smaller than the 45μm particle size of commercially available Enrofloxacin—ensuring more thorough absorption.
① Accelerated oral absorption efficiency: Rapid absorption within 15 minutes post-administration, achieving peak plasma concentration within 1 hour for swift therapeutic effect.
② Improved bioavailability​: Bioavailability reaches 91.8%, surpassing that of comparable market products (72%~80%)​​.
2) Coating-like tableting process, diverse administration methods
Enroserene employs a coating-like tableting process that effectively mitigates the impact of external environmental factors—such as light, humidity, and temperature—on drug absorption. Enroserene supports multiple administration methods including ​​direct feeding,powder mixing, and administration via drinking water,with no compromise to pharmaceutical efficacy.
3) Cross-shaped score line,facilitates accurate  splitting
Enroserene features a cross-shaped score line for precise tablet division, enabling precise dosing for smaller animals and streamlining medication administration.
4) Broad-spectrum antibacterial activity with High efficacy against Mycoplasma
Enroserene demonstrates ​​exceptional efficacy against Mycoplasma, while also exhibiting potent bactericidal effects against a wide range of pathogens, including:Escherichia coli, Klebsiella spp., Salmonella spp., Proteus spp., Pseudomonas aeruginosa, Haemophilus spp., Pasteurella multocida, Mannheimia haemolytica, Staphylococcus aureus, Streptococcus spp.,also exhibits bactericidal effects against Gram-negative bacteria.

Indication:
1) Upper respiratory infections in dogs and cats: acute inflammations of the nasal cavity, pharynx, and larynx, etc.
2) Lower respiratory infections in dogs and cats: acute/chronic bronchitis, pneumonia, pleural empyema (pyothorax), etc.
3) Digestive system infections in dogs and cats: bacterial enteritis/colitis, cholecystitis, suppurative cholangiohepatitis, etc.
4) Urogenital infections in dogs and cats: urinary tract infections (utis), mastitis, pyometra, etc.
5) Infections in exotic pets: bacterial infections in birds, ferrets, reptiles, rodents, rabbits, etc.

*Use only under the guidance of a veterinarian
Leave Message
Home Product About Contact